ACM
IMVT icon

ADAR1 Capital Management’s Immunovant IMVT Stock Holding History

ADAR1 Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,200
Closed -$291K – 255
2024
Q3 		$291K Buy
+10,200
New +$301K 0.05% 143

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ADAR1 Capital Management's IMVT Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Immunovant (IMVT) stake by 13% in Q2 2026, selling an estimated $10.6M and leaving 2,330,716 shares worth $89.8M. The position accounts for 4.11% of the portfolio, ranked #5.

ADAR1 Capital Management first reported a position in IMVT in Q4 2023 and has held it in 11 quarters since. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • ADAR1 Capital Management held 2,330,716 shares of Immunovant worth $89.8M as of Q2 2026.
  • ADAR1 Capital Management sold 348,294 Immunovant shares in Q2 2026, an estimated $10.6M.
  • Immunovant made up 4.11% of ADAR1 Capital Management's portfolio in Q2 2026, its #5 holding.
  • ADAR1 Capital Management first reported a position in Immunovant in Q4 2023 and has held it in 11 quarters since.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.